Cerus Corporation 10-Q Summary
Business context and reporting period
Cerus Corporation develops and commercializes the INTERCEPT Blood System for pathogen reduction of blood components, including platelets, plasma and cryoprecipitation products. The red blood cell system remains in development. This Form 10-Q covers the quarter ended March 31, 2024, and compares results with the quarter ended March 31, 2023.
Key financial metrics
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Total revenue | $43.4 million | $38.5 million | 13% |
| Product revenue | $38.4 million | $31.0 million | 24% |
| Government contract revenue | $5.0 million | $7.5 million | (33%) |
| Gross profit on product revenue | $21.3 million | $17.3 million | 23% |
| Product gross margin | 55% | 56% | Down 1 percentage point |
| Operating loss | $(8.0) million | $(14.1) million | Loss narrowed |
| Net loss attributable to Cerus | $(9.7) million | $(15.6) million | Loss narrowed |
| Loss per share | $(0.05) | $(0.09) | Improved |
| Net cash from operating activities | $2.0 million | $(8.5) million | Improved by $10.5 million |
Product revenue growth was primarily driven by higher disposable platelet kit sales to U.S. customers, while government contract revenue declined mainly because of lower BARDA activity following completion of the ReCePI study. Operating expenses were $34.3 million, down from $38.9 million, including R&D of $14.5 million and selling, general and administrative expense of $19.8 million.
At March 31, 2024, cash and cash equivalents were $20.5 million, short-term investments were $51.7 million and restricted cash was $1.7 million, for total cash, investments and restricted cash of $73.9 million. Working capital was $81.6 million. Total debt was $84.9 million, consisting of $20.1 million current debt and $64.8 million non-current debt. The term loan carried an interest rate of approximately 12.2% at quarter-end. The company was in compliance with its debt covenants.
Cash increased by $8.9 million during the quarter to $22.2 million, including restricted cash. Operating activities provided $2.0 million, investing activities provided $1.4 million and financing activities provided $5.6 million. Financing cash flow included a $5.0 million term-loan draw completed on March 27, 2024.
Material changes versus the prior comparable period
- Product revenue increased $7.4 million, led by U.S. platelet kit volume growth.
- Government contract revenue decreased $2.5 million, primarily due to lower BARDA revenue.
- Product gross margin declined to 55% from 56%, reflecting geographic and product mix.
- R&D expense declined 17% and SG&A expense declined 8%, primarily following the 2023 workforce reduction.
- Interest expense increased 39% to $2.2 million because of higher interest rates and increased debt.
- Accounts receivable declined to $22.5 million from $35.5 million, while total inventories declined to $57.8 million from $59.4 million.
- The company borrowed the remaining $5.0 million available under Term Loan Tranche 3 during the quarter.
- Shares outstanding increased; weighted-average basic shares rose to 182.1 million from 178.3 million.
Guidance, outlook, commentary and risks
Management expects product revenue, particularly disposable kit revenue, to increase in future periods as U.S. adoption and international commercialization progress. The company does not anticipate government contract revenue will materially increase in future periods. Management stated that available cash, short-term investments, product-sale receipts and government-contract receipts should be sufficient to meet capital requirements for at least the next 12 months, but this assessment depends on assumptions that may prove incorrect.
The company expects a decision on its European CE Certificate of Conformity application for the red blood cell system in the second half of 2024, although timing and approval are uncertain. It anticipates initiating a modular FDA PMA submission in the second half of 2025 and completing the final module in the second half of 2026, subject to successful completion of the RedeS study and other regulatory requirements.
- BARDA had committed funding of up to $185.5 million as of March 31, 2024, with a potential total funding opportunity of up to $270.2 million through September 2026. Additional option funding is discretionary and BARDA may terminate the agreement for convenience.
- The company expects higher future interest expense after the additional term-loan draw. Unless debt terms are restructured or extension conditions are met, term-loan principal amortization is expected to begin in April 2026.
- The company relies substantially on third-party manufacturers, including Fresenius as the sole supplier of finished disposable kits for platelet and plasma systems. Supply interruptions, component obsolescence, manufacturing nonconformities and regulatory issues could restrict sales.
- The current illuminator is being phased out because of component obsolescence. Sales may be limited until a redesigned illuminator is validated, approved and available.
- Commercial adoption depends on concentrated customers, reimbursement, regulatory approvals, customer operating practices and competition. The American Red Cross represented 36% of product revenue and EFS represented 14% in Q1 2024.
- The company continues to expect losses and may require additional debt or equity financing. Its at-the-market facility had approximately $96.8 million available at quarter-end, but no shares were sold under the facility during the quarter.
- The company is responding to a Department of Justice Antitrust Division civil investigative demand concerning contracting and information-exchange practices. No claim or proceeding had been initiated as of the filing date, but costs and potential penalties or business changes remain uncertain.
- As of March 31, 2024, the company had $26.8 million of short-term and $3.0 million of long-term purchase commitments not recorded on the balance sheet.
Important facts for investors to verify
- Whether U.S. platelet kit growth is sustained and converts into improved operating leverage and profitability.
- The timing and outcome of the red blood cell system’s European certification and the RedeS trial and FDA PMA pathway.
- BARDA option exercises, reimbursement timing and any changes to government funding.
- Liquidity after considering $84.9 million of debt, floating interest rates and potential principal amortization beginning in 2026.
- Availability and qualification of Fresenius production capacity, redesigned illuminators and other sole-source components.
- Progress in commercializing IFC and obtaining additional blood-center manufacturing licenses.
- Developments in the DOJ antitrust inquiry and any related financial or operational consequences.
- The company’s ability to fund ongoing operations without substantial equity dilution or additional restrictive debt.